The effect of bupivacaine liposome thoracic paravertebral nerve block on the postoperative recovery quality of patients undergoing bariatric surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600120917

Enrollment

Unknown

Registered

2026-03-23

Start date

2026-03-23

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric surgery

Interventions

Group B (bupivacaine liposome group):Paravertebral nerve block with liposomal bupivacaine

Group L(ropivacaine group):Paravertebral nerve block with ropivacaine

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Age range: 18 - 55 years old. ASA classification: I - III. BMI: 28 - 45 kg/m^2. Patients scheduled for laparoscopic sleeve gastrectomy.

Exclusion criteria

Exclusion criteria: 1. Blood diseases or coagulation disorders; 2. Presence of mental or neurological disorders; 3. Allergy to local anesthetics or analgesics; 4. Renal or liver dysfunction; 5. Cardiac conduction block; 6. Unstable coronary artery disease; 7. NYHA classification of heart function 3-4; 8. Pregnancy or planning to get pregnant; 9. Severe alcoholism or long-term use of analgesics due to chronic pain.

Design outcomes

Primary

Measure	Time frame
The QOR-15 score at 24 hours after the operation;	—

Secondary

Measure	Time frame
The QOR-15 score at 48 hours postoperatively;Numerical Rating Score;Morphine consumption;The incidence of postoperative adverse reactions;	—

Countries

China

Contacts

Public ContactPengfei Wang

Department of Anesthesiology and Perioperative Medicine, Zhengzhou Central Hospital Affiliated to Zhengzhou University

854892658@qq.com+86 159 3718 4246

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026